IL18 and metabolic dysfunction-associated steatotic liver disease: Experimental studies in IL-18 knockout mice have demonstrated the development of NAFLD, which can be ameliorated by recombinant IL-18, indicating its role of IL-18 in controlling the onset and progression of NAFLD [103].